Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries EQRx, Inc. - Common Stock (NQ: EQRX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Nov 8, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about EQRx, Inc. - Common Stock EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX October 06, 2023 From Kahn Swick & Foti, LLC Via Business Wire EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders September 27, 2023 From Robbins LLP Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX) August 10, 2023 From Brodsky & Smith LLC Via GlobeNewswire EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX August 02, 2023 From Kahn Swick & Foti, LLC Via Business Wire EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders August 01, 2023 From Halper Sadeh LLC Via Business Wire Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital August 01, 2023 From Revolution Medicines, Inc.; EQRx, Inc. Via GlobeNewswire EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results May 08, 2023 From EQRx, Inc. Via GlobeNewswire EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023 April 27, 2023 From EQRx, Inc. Via GlobeNewswire EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders April 21, 2023 From Robbins LLP Via Business Wire EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress February 23, 2023 From EQRx, Inc. Via GlobeNewswire EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From EQRx, Inc. Via GlobeNewswire EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer December 19, 2022 From EQRx, Inc. Via GlobeNewswire EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer December 02, 2022 From EQRx, Inc. Via GlobeNewswire EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results November 10, 2022 From EQRx, Inc. Via GlobeNewswire EQRx to Participate in the Jefferies 2022 London Healthcare Conference November 07, 2022 From EQRx, Inc. Via GlobeNewswire EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 October 28, 2022 From EQRx, Inc. Via GlobeNewswire EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 July 28, 2022 From Eqrx, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.